RP5063

Phase 2Small molecule

RReviva Pharmaceuticals

RP5063 is one of 58 small molecule programs targeting Schizoaffective Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Schizoaffective DisorderActive, not recruiting

Schizoaffective DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

66 competitors in Schizoaffective Disorder

#DrugCompanyPhaseTrials

Risperdal

WWim Janssens

Approved

18 2

Zyprexa

MMODAG GmbH

Approved

10 3

Nicorette

Pfizer

Approved

1 4

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Approved

8 5

Abilify

Otsuka

Approved

6 6

Diamox

Estrace

Epidiolex

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Approved

1 10

Haldol

DDePuy Orthopaedics

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Schizoaffective Disorder1 trial

RP5063 in Subjects With Schizophrenia or Schizoaffective Disorder

Completed·RReviva Pharmaceuticals·Phase 2·NCT01490086·234 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for RP5063. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — RP5063 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for RP5063. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Reviva Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: RReviva Pharmaceuticals

RP5063

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Schizoaffective Disorder1 trial

References

Drug Info

Quick Facts

Related News